| abstract |
6-(2-hydroxy-2-methylpropoxy)-4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)pyridin -3-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile, or a pharmaceutically acceptable salt, amorphous form, polyamorphous form, or pharmaceutical composition (including solid formulations or liquid formulations) thereof and the use thereof for treating diseases and disorders that can be treated with a ret kinase inhibitor, such as ret-associated diseases and disorders, for example, proliferative disorders, such as cancers, including hematologic cancers and solid tumors, and gastrointestinal disorders such as ibs are described. |